Lung Tumors With EGFR Mutations Are More Likely to Be Treated With TKIs

10 to 15% of North American patients diagnosed with non-small cell lung cancer have cancers with EGFR mutations. Patients more likely to have these cancers are women, non-smokers, people from Asia and patients with adenocarcinoma histopathology. Approximately 90% of these mutations are point mutations within the EGFR tyrosine kinase domain,. resulting in hyperactivation of both EGFR kinase activity and downstream signaling. Lung tumors at harbor activating mutations within theEGFR kinase domain display high sensitivity to small molecule EGFR ty Rosine kinase inhibitors or TKIs.